<DOC>
	<DOCNO>NCT01635803</DOCNO>
	<brief_summary>The primary objective demonstrate non-inferiority bevacizumab treatment patient macular edema secondary retinal vein occlusion ( branch central ) determine change best-corrected visual acuity study eye baseline month 6 .</brief_summary>
	<brief_title>Comparing Effectiveness Costs Bevacizumab Ranibizumab Patients With Retinal Vein Occlusions ( BRVO )</brief_title>
	<detailed_description>Objective : compare effectiveness cost 1.25 mg bevacizumab 0.5 mg ranibizumab , give monthly intravitreal injection 6 month . Study Design : This randomize , control , double mask , clinical trial 296 patient 7 academic trial centre The Netherlands . Study population : patient older 18 year age macular edema secondary retinal vein occlusion best correct visual acuity ( BCVA ) score 78 20 letter study eye . Outcomes : The primary outcome measure change BCVA study eye baseline month 6 . Secondary outcome amongst others proportion patient gain 15 letter and/or BCVA 20/40 6 month cost per quality adjust life-year two treatment</detailed_description>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Male female patient &gt; 18 year age vision loss due foveal centerinvolved ME secondary branch central retinal vein occlusion diagnose within 6 month study initiation , sign informed consent ; BCVA equal 24 less equal 78 letter study eye screen use ETDRS like visual acuity test chart test distance 4 meter Mean central subfield thickness 275 micron 2 OCT measurement . 1 . Women childbearing potential . 2 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive serum pregnancy test ( human chorionic gonadotropin &gt; 5 mIU/ml ) ; 3 . Inability comply study procedure ; 4 . Active intraocular inflammation either eye enrolment ; 5 . Any active infection either eye time enrolment ; 6 . History uveitis either eye time ; 7 . Structural damage within 600 micron center macula study eye likely preclude improvement visual acuity follow resolution macular edema , include atrophy retinal pigment epithelium , subretinal fibrosis , laser scar ( ) , epiretinal membrane involve fovea organize hard exudate plaque ; 8 . Uncontrolled ( neovascular ) glaucoma study eye screening . ( IOP &gt; 24 mmHg medication accord investigator 's judgment ) ; 9 . Evidence vitreomacular traction study eye ; 10 . Patients monocular Snellen VA nonstudy eye â‰¤ 1/300 visit 1 ; 11 . Any intraocular surgery study eye within 3 month prior randomization ; 12 . Planned medical surgical intervention 6months study period ; 13 . Panretinal laser photocoagulation study eye within 3 month prior study ; 14 . Focal/grid laser photocoagulation study eye 3 month prior study entry ; 15 . Treatment antiangiogenic drug study eye within 3 month prior randomization ; 16 . Use investigational drug time enrolment , within 3 month 5 halflives enrolment , whichever longer ; 17 . History intravitreal corticosteroid study eye within 4 month prior randomization ; 18 . Ocular condition study eye require chronic concomitant therapy topical ocular systemically administered corticosteroid ; 19 . History stroke transient ischemic attack ( TIA ) within 6 month prior enrolment ; 20 . History myocardial infarction within 3 month prior randomization ; 21 . Current use likely need systemic medication know toxic lens , retina optic nerve , include deferoxamine , chloroquine/hydroxychloroquine ( Plaquenil ) , tamoxifen , phenothiazine ethambutol ; 22 . Known hypersensitivity fluorescein , bevacizumab ranibizumab component thereof drug similar chemical class ; 23 . Any type advance , severe unstable disease treatment , may interfere primary and/or secondary variable evaluation include medical condition could expect progress , recur , change extend may bias assessment clinical status patient significant degree put patient special risk ; 24 . Ocular disorder study eye may confound interpretation study result , compromise visual acuity require medical surgical intervention 6 month study period , include cataract , retinal vascular occlusion , retinal detachment , macular hole , choroidal neovascularisation cause ( e.g. , AMD , ocular histoplasmosis , pathologic myopia ) ; 25 . Prior episode RVO ; 26 . Evidence examination sightthreatening diabetic retinopathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>retinal vein occlusion</keyword>
	<keyword>randomize clinical trial</keyword>
	<keyword>Macular edema</keyword>
</DOC>